CAI Maintained by JP Morgan -- Price Target Raised to $35

JP Morgan maintained an Overweight rating for Caris Life Sciences Inc (CAI) and raised its price target to $35 from $25, citing confidence in the company's future performance. CAI's P/E ratio is 81.33x, higher than its 5-year median, and its GF Score™ is 11/100, indicating areas for improvement. Insider activity shows significant selling. CAI specializes in molecular science and technology, focusing on precision medicine in oncology.

Original reporting
Published Oct 14, 2026, 8:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 9:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$CAI
Bullish
medium confidence
Mentioned
$CAI
Relevance
6/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$CAIBullishMed
01

Why it matters

Analyst upgrade may prompt short‑term buying, but valuation concerns remain.

02

Market read

The target raise could spark buying interest in CAI and related biotech stocks.

03

What to watch

Recent insider selling of $27 M could signal internal concerns.

Relevance 6/10Novelty 7/10Timing: pre‑market today

Background

Caris Life Sciences (CAI) provides molecular profiling services for oncology, leveraging AI/ML technologies.

Company-level read

Ticker impact

$CAIBullishMedium confidence
Context

JP Morgan maintained Overweight and raised the price target for CAI from $25 to $35, indicating a bullish outlook.

Expected impact

likely upward pressure as investors price in the higher target

Evidence & confidence

The 40% target hike reflects JP Morgan's confidence in CAI's oncology platform and AI-driven diagnostics, which may attract buying interest.

Market effects

Positive signal for biotech and AI‑driven diagnostics sector.

U.S. biotech stocks may see modest gains.

Limited to investors tracking US biotech equities.

Counterpoint

High valuation (81x P/E) and low GF Score may limit upside despite target raise.

Key entities

  • JP Morgan

    Maintained Overweight and raised price target to $35.

  • Caris Life Sciences Inc

    Biotech firm focused on precision oncology diagnostics.

Related articles

$CAIMed

Caris Life Sciences Inc (CAI) Q3 2026 Earnings Call Highlights: Record Revenue, Sixth

Caris Life Sciences (CAI) reported Q3 2026 revenue growth, but faced negative free cash flow of $39.7M due to capital expenditures. Operating expenses rose $48.1M year-over-year, and full-year GAAP opex guidance was raised to ~$620M. New product launches without reimbursement may pressure margins. Q4 pharma R&D services revenue is expected to decline sequentially. The company is expanding its commercial team and expects positive free cash flow in Q4.

$CAIHigh

Caris Life (CAI) Q3 2026 Earnings Call Transcript

Caris Life (CAI) reported Q3 2026 earnings, highlighting 21% year-over-year clinical case growth and 27% revenue increase to $275M. The company launched new products, including Caris Assure for monitoring and plans to launch Caris Confirm for MRD in December. Caris Detect, their early-stage cancer detection test, is gaining market traction. The company maintained profitability with adjusted EBITDA of $44.4M and net income of $15.3M.

$CAIMed

TD Cowen raises Caris Life Sciences stock price target on pipeline

TD Cowen raised its price target for Caris Life Sciences (CAI) to $38 from $36, maintaining a Buy rating. The company reported Q3 sales beating expectations by 9%, with revenue up 85% year-over-year and a 70% gross margin. Despite this, shares fell 15% post-market due to an earnings miss. The stock has gained 65% since pre-Q2 levels, but InvestingPro suggests it may be overvalued.